FSD Pharma Inc. - Class B Subordinate Voting Shares (NQ:HUGE)

0.0899 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FSD Pharma Inc. - Class B Subordinate Voting Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Filing of Complaint, Update on Spin-Out Transaction

May 15, 2023

Via Investor Brand Network

FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution

May 12, 2023

From FSD Pharma Inc.

Via Business Wire

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Secures $2.81M in Cost Awards from Dr. Raza Bokhari

May 11, 2023

Via Investor Brand Network

FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari

May 11, 2023

From FSD Pharma Inc.

Via Business Wire

Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed ↗

May 10, 2023

FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first...

Via Benzinga

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial

May 10, 2023

Via Investor Brand Network

FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort

May 10, 2023

From FSD Pharma Inc.

Via Business Wire

Sidoti's Micro-Cap Virtual May Conference

May 09, 2023

Via ACCESSWIRE

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗

May 08, 2023

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

Via Benzinga

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present at Sidoti Virtual Investor Conference

May 08, 2023

Via Investor Brand Network

FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11

May 08, 2023

From FSD Pharma Inc.

Via Business Wire

Lawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret Misappropriation ↗

May 05, 2023

GBB Drink Lab, which makes the world’s first formulated drink that aids in rapid blood alcohol detoxification - a handy tool, has filed a lawsuit against the psychedelics biotech company FSD Pharma...

Via Benzinga

GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation

May 05, 2023

GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation

Via News Direct

Topics Lawsuit

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Dynamic Duo of Celsius Holdings Fame join FSD Pharma calling Medical Product under Development “Unique and Disruptive”

April 19, 2023

Via AB Newswire

Topics Bankruptcy

North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry

April 18, 2023

EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END

Via FinancialNewsMedia

GBB Drink Lab Sends a Cease-and-Desist Demand

April 17, 2023

FSD Pharma Breached NDA with GBB After GBB Terminates Acquisition Discussions

Via News Direct

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More ↗

April 17, 2023

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules

Via Benzinga

Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis ↗

April 17, 2023

FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis.

Via Benzinga

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Completes Critical Step in Advancing Lucid-MS Pipeline

April 17, 2023

Via Investor Brand Network

FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

April 17, 2023

From FSD Pharma Inc.

Via Business Wire

EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics ↗

April 13, 2023

The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.

Via Benzinga

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Spin-Out Plan, Announces Shareholder Meeting

April 12, 2023

Via Investor Brand Network

FSD Pharma To Spin Out New Publicly Trading Subsidiary As Distribution To Shareholders ↗

April 12, 2023

Psychedelics biotech company FSD Pharma Inc.

Via Benzinga

FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023

April 12, 2023

From FSD Pharma Inc.

Via Business Wire

FSD Pharma Announces Filing of Year-End 2022 Results

March 31, 2023

From FSD Pharma Inc.

Via Business Wire

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Board Appointment of Gerry David

March 30, 2023

Via Investor Brand Network

FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors

March 30, 2023

From FSD Pharma Inc.

Via Business Wire

Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More ↗

March 27, 2023

Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses

Via Benzinga

FSD Pharma's Australian Entity To Proceed With Phase I Trial For Major Depressive Disorder ↗

March 23, 2023

Biotech company FSD Pharma Inc. (NASDAQ: HUGE)’s Australian business FSD Pharma Australia Pty Ltd. has been approved by the Alfred Ethics Committee to begin a Phase 1 clinical trial of next-gen drug...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.